Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Completed × Chemotherapy-induced Neutropenia × Clear all

Phase

Phase 3 2 Phase 2 2 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 36 Neoplasms 34 Prostatic Neoplasms 30 Leukemia, Myeloid, Acute 21 Colorectal Neoplasms 21 Carcinoma, Non-Small-Cell Lung 20 Precursor Cell Lymphoblastic Leukemia-Lymphoma 16 Neoplasm Metastasis 14 Stomach Neoplasms 12 Lung Neoplasms 12 Polycystic Ovary Syndrome 11 Multiple Myeloma 11 Carcinoma, Hepatocellular 11 Pancreatic Neoplasms 9 Urinary Bladder Neoplasms 8 Motor Activity 8 Lymphoma 8 Recurrence 7 Myelodysplastic Syndromes 7 Liver Neoplasms 7 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7 Leukemia 7 Head and Neck Neoplasms 7 Esophageal Neoplasms 7 Brain Neoplasms 7 Pain 6 Ovarian Neoplasms 6 Lymphoma, Non-Hodgkin 6 Lymphoma, Follicular 6 Hematologic Neoplasms 6

Interventions

pegfilgrastim 1 balugrastim 1 Drug Therapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00837265 2024-04-03

NEUGR-002

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2/3 Completed

334 enrolled 16 charts

Chemotherapy-induced Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡